Heart failure related cardiotoxicity in breast cancer survivors: a scoping review

Abstract

Background: Breast cancer is the most common malignancy among women globally and the second most frequently diagnosed cancer overall, with 2.3 million new cases reported in 2022. While advances in therapy have substantially improved survival, cardiovascular disease (CVD) has emerged as the leading cause of non-cancer mortality in this population. Real-world evidence on the incidence and trajectory of heart failure (HF) and treatment-related cardiotoxicity remains limited, with existing studies often constrained by small sample sizes or narrow therapeutic focus. This scoping review aimed to synthesise evidence on the incidence of HF, cardiovascular mortality, and all-cause mortality in indivi..